TABLE 1.
Baseline characteristics of hVISA and VSSA patients
| Parametera | Value for the cohort |
P value | |
|---|---|---|---|
| hVISA (n = 29) | VSSA (n = 58) | ||
| Median age (yr [IQR]) | 63.0 (56.0–76.0) | 59.00 (50.0–68.25) | 0.117 |
| Median wt (kg [IQR]) | 70.0 (63.5–87.5) | 69.9 (60.4–79.7) | 0.595 |
| Median Charlson score (IQR) | 5 (2.5–7.0) | 5 (2.0–7.0) | 0.995 |
| Median SOFA score (IQR)b | 7.0 (5.0–8.0) | 5 (3.0–8.0) | 0.092 |
| No. (%) of female patients | 10 (34.5) | 24 (41.4) | 0.534 |
| No. (%) of African American patients | 21 (72.4) | 40 (69.0) | 0.907 |
| Clinical factors (no. of patients [%]) | |||
| Diabetes | 10 (34.5) | 22 (37.9) | 0.753 |
| History of CVA | 7 (24.1) | 16 (27.6) | 0.731 |
| Any respiratory pathology | 13 (44.8) | 33 (56.9) | 0.241 |
| HIV/AIDS | 2 (6.9) | 3 (5.2) | 0.745 |
| Liver disease | 2 (6.9) | 7 (12.1) | 0.455 |
| Intravenous drug use | 8 (27.6) | 11 (19.0) | 0.359 |
| Hemodialysis | 3 (10.3) | 4 (6.9) | 0.577 |
| eGFR (median [IQR]) | |||
| Baseline | 60.0 (36.5–100.0) | 86.0 (60.0–115.5) | 0.022 |
| At start of antimicrobial treatment | 31.5 (17.3–68.0) | 62.0 (38.0–96.5) | 0.013 |
| Prior hospitalization (no. of patients [%]) | 15 (51.7) | 32 (55.2) | 0.761 |
| Antibiotic use in the last 30 days (no. of patients [%]) | 7 (24.1) | 7 (12.1) | 0.149 |
| Admission data (no. of patients [%]) | |||
| Home | 19 (65.5) | 35 (60.3) | 0.851 |
| SNF | 8 (27.6) | 15 (25.9) | 1.000 |
a
IQR, interquartile range; SOFA, sequential organ failure assessment; CVA, cerebrovascular accident; HIV, human immunodeficiency virus; eGFR, estimated glomerular filtration rate; SNF, skilled nursing facility.
b
First 24 h after hospital admission.